Elanco Animal Health Incorporated announced on September 19, 2024, that the U.S. Food and Drug Administration (FDA) has approved Zenrelia (ilunocitinib tablets). This once-daily oral JAK inhibitor is indicated for the control of pruritus associated with allergic dermatitis and atopic dermatitis in dogs at least 12 months of age.
Zenrelia is positioned to offer a new solution in the canine dermatology market, with Elanco stating it is a highly effective, convenient, and safe option. A head-to-head study comparing Zenrelia to the market incumbent JAK inhibitor showed it was at least as effective at the primary endpoint on Day 28.
The product's label includes a boxed warning regarding safety related to concurrent vaccine administration, advising discontinuation for at least 28 days to 3 months prior to vaccination. Elanco expects the launch list price to be approximately 20% less for most dogs compared to the current market incumbent, aiming to provide a more affordable option for pet owners.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.